Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

FluoroPharma Medical, Inc. (FPMI) Bases Success on Unique Management Team Mix

In the developing high tech world of advanced medical technology, company leaders require a unique combination of technical vision, business acuity, and an in-depth knowledge of the special requirements associated with human health care. FluoroPharma Medical, developer of advanced diagnostic imaging products used in PET scanning, has based its future on the embodiment of this principle, sporting a management team comfortable with the industry’s diverse aspects.

• David Elmaleh, PhD (Chairman, Director, Chief Scientific Advisor) – The Scientific Founder of FluoroPharma, an Associate Professor of Harvard Medical School, and Director of Contrast Media Chemistry at the Massachusetts General Hospital, Dr. Elmaleh is the inventor of three drugs currently in use or in late stage clinical trials. He’s done extensive research on imaging compounds, and is a co-author of over 120 publications, as well as being an inventor of more than 40 issued and pending patents. He is also the Scientific Founder of Biostream, now Molecular Insight Pharmaceuticals, and other start-ups.

• Thiis Spoor, MBA (Director, CEO, and President) – Previously the CFO for Sunstone BioSciences, Mr. Spoor holds a degree in Nuclear Pharmacy, and an MBA from Columbia with concentrations in Finance and Accounting. He’s been a guest lecturer at Columbia Business School, Kings College in London, and the University of Newcastle in Australia. He has extensive experience in helping pharmaceutical and medical device companies evaluate their global revenue potential, given the complex interplay of regulatory approvals and other factors. He has also performed equity research analysis for JP Morgan and Credit Suisse, covering the Biotechnology and Medical Device industries.

• Bovan Goumnerov, MD (COO & VP Clinical Trials) – Dr. Goumnerov has held executive level positions in healthcare and biomedical research, including as President of VasoStent, Inc., and as Managing Director of CardioVas, Inc., both medical device start-ups in cardiac imaging and therapy. He’s done research in surgery and molecular biology at the Massachusetts General Hospital and The Shriners Burn Hospital for Children in Boston, where he held academic appointments with Harvard Medical School. He is co-author of many scientific publications.

For more information, see the company website at www.FluoroPharma.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html